Please do not leave this page until complete. This can take a few moments.
New Haven’s Trevi Therapeutics announced positive results on Monday from the completed clinical trial of its flagship medication in patients with chronic cough caused by a serious lung ailment.
Haduvio, Trevi’s oral, extended-release formulation of the synthetic opioid agonist-antagonist nalbuphine, showed positive results from the full set of subjects in a Phase 2 clinical trial, Trevi reported. Patients who took the drug in the trial were adults with idiopathic pulmonary fibrosis (IPF), a serious disease that causes scar tissue to grow inside the lungs which impairs breathing and causes coughing.
Early promising results prompted Trevi to end enrollment in the trial early, in March, although patients already enrolled were allowed to complete the trial. The latest announcement about Haduvio’s results comes from the full set of subjects who took part.
Patients reported a 75.1% reduction in daytime cough frequency when taking Haduvio, according to a statement. Patients showed consistent reductions in cough frequency over 24 hours and during the daytime when compared to a placebo.
Trevi President and CEO Jennifer Good said, “There are no approved therapies for chronic cough in these patients, and we are excited to continue our development in this indication and look forward to starting our next clinical trial for these patients in the first half of 2023.”
In June, Trevi reported positive results in a trial of Haduvio for the treatment of prurigo nodularis, a chronic inflammatory skin disease that causes intense itching.
Contact Liese Klein at lklein@newhavenbiz.com.
The Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThe Hartford Business Journal 2025 Charity Event Guide is the annual resource publication highlighting the top charity events in 2025.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments